United-Guardian, Inc. (UG)
NASDAQ (NMS) NASDAQ (NMS) Primary 
UG Q3 Profit Falls Y/Y on Weak Cosmetics Sales, Stock Declines 10%
United-Guardian's Q3 earnings fall y/y on weak cosmetic sales, pressuring margins and sending UG shares down even as pharma and medical lines grow.
UG Q2 Earnings Fall Y/Y on Weak Cosmetic Sales, Pharma Gains
United-Guardian's Q2 earnings fall on weak cosmetic sales, partly offset by gains in pharmaceuticals and medical lubricants, with recovery hopes ahead.
United-Guardian Q1 Earnings Fall 39% Y/Y as Cosmetic Sales Tumble 63%
UG's Q1 earnings drop 39% as cosmetic sales plunge, offsetting gains in pharmaceuticals and medical lubricants.
United-Guardian Stock Dips 9.6% Despite Robust 2024 Sales & Earnings
UG's 2024 sales grow 12% y/y and earnings rise. Yet. the stock falls amid supply challenges and muted guidance, sparking mixed investor sentiment.
United-Guardian Reports Y/Y Rise in Q3 Earnings, Flat Revenues
UG's Q3 earnings gain from effective cost management and increased demand for its cosmetic ingredients segment.
United-Guardian (UG) Posts Y/Y Q2 Earnings & Sales Growth
Higher cosmetic ingredient sales aid United-Guardian's (UG) earnings in Q2.
Zacks Initiates Coverage of United-Guardian With Outperform Recommendation
Discover why Zacks rates United-Guardian (UG) as "Outperform," being the first on Wall Street to initiate the coverage of the stock. Explore UG's robust growth in cosmetic ingredient sales, a strong financial foundation and promising product launches, making it an attractive option for investors.
